scout
News|Videos|January 19, 2024

Safety and Clinical Experience of XPO1 Inhibitors in R/R MM Patients

Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME